The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
 
Laura Spring
No Relationships to Disclose
 
Andrzej Niemierko
No Relationships to Disclose
 
Amy H. Comander
No Relationships to Disclose
 
Kerry Lynn Reynolds
No Relationships to Disclose
 
Susan A. Sajer
No Relationships to Disclose
 
Jennifer Shin
No Relationships to Disclose
 
Elena F Brachtel
No Relationships to Disclose
 
Michelle Connolly Specht
No Relationships to Disclose
 
Barbara L. Smith
No Relationships to Disclose
 
Alphonse G. Taghian
No Relationships to Disclose
 
Jeffrey M. Peppercorn
Employment - GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Research Funding - Pfizer
 
Steven J. Isakoff
Consulting or Advisory Role - BIND Biosciences; Myriad Genetics
Research Funding - Abbvie; Genentech; PharmaMar
Travel, Accommodations, Expenses - Genentech; Myriad Genetics
 
Beverly Moy
Consulting or Advisory Role - MOTUS (I); Olympus (I)
 
Aditya Bardia
Consulting or Advisory Role - Genentech; Immunomedics; Novartis